Abstract
Historically, most of anticancer drugs were delivered by the intravenous route which is the most direct one leading to immediate and complete bioavailability of the drugs. However, this administration route could result in several side effects and requires a clinic or hospitalization visit, nursing and palliative treatment. For these latter reasons, oral delivery of anticancer drugs is nowadays more and more considered, including already marketed drugs. In this first review, we aim to identify general considerations for the oral delivery of anticancer drugs. In the second and the third reviews we respectively discuss the prodrug strategy and the use of drug delivery systems to improve the oral bioavailability of anticancer drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
